 Shanlee Davis
Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Klinefelter Syndrome | 18 | 2026 | 69 | 7.320 |
Why?
| | Turner Syndrome | 10 | 2025 | 64 | 5.010 |
Why?
| | Trisomy | 4 | 2025 | 78 | 2.610 |
Why?
| | Sex Chromosome Aberrations | 9 | 2025 | 69 | 2.450 |
Why?
| | Sex Chromosome Disorders | 3 | 2025 | 27 | 2.280 |
Why?
| | Neurodevelopmental Disorders | 3 | 2025 | 226 | 2.110 |
Why?
| | Testosterone | 6 | 2025 | 413 | 1.960 |
Why?
| | XYY Karyotype | 4 | 2025 | 24 | 1.800 |
Why?
| | Body Height | 2 | 2025 | 200 | 1.310 |
Why?
| | Chromosomes, Human, X | 5 | 2025 | 76 | 1.310 |
Why?
| | Mosaicism | 4 | 2024 | 73 | 1.270 |
Why?
| | Oxandrolone | 3 | 2018 | 6 | 1.200 |
Why?
| | Mental Disorders | 4 | 2025 | 1157 | 1.080 |
Why?
| | Child Development | 2 | 2025 | 484 | 1.070 |
Why?
| | Sex Chromosome Disorders of Sex Development | 3 | 2025 | 17 | 1.060 |
Why?
| | Cardiovascular Diseases | 5 | 2025 | 2185 | 0.930 |
Why?
| | Growth Charts | 1 | 2025 | 20 | 0.920 |
Why?
| | Efficiency, Organizational | 1 | 2026 | 141 | 0.890 |
Why?
| | Child | 31 | 2026 | 22680 | 0.850 |
Why?
| | Puberty | 4 | 2024 | 135 | 0.820 |
Why?
| | Ambulatory Care Facilities | 1 | 2026 | 269 | 0.810 |
Why?
| | Anti-Mullerian Hormone | 2 | 2020 | 57 | 0.780 |
Why?
| | Body Composition | 4 | 2025 | 689 | 0.750 |
Why?
| | Ambulatory Care | 1 | 2026 | 608 | 0.680 |
Why?
| | Testis | 3 | 2018 | 162 | 0.680 |
Why?
| | Monosomy | 1 | 2021 | 10 | 0.670 |
Why?
| | Registries | 4 | 2024 | 2410 | 0.650 |
Why?
| | Disorders of Sex Development | 1 | 2021 | 40 | 0.650 |
Why?
| | Sex Chromosomes | 4 | 2025 | 53 | 0.640 |
Why?
| | Patient Care Team | 1 | 2026 | 696 | 0.640 |
Why?
| | Inhibins | 1 | 2020 | 41 | 0.630 |
Why?
| | Ovarian Reserve | 1 | 2020 | 17 | 0.630 |
Why?
| | Dyslipidemias | 1 | 2022 | 184 | 0.630 |
Why?
| | Mitochondria, Muscle | 1 | 2021 | 120 | 0.620 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2020 | 40 | 0.620 |
Why?
| | Phenotype | 7 | 2025 | 3157 | 0.620 |
Why?
| | Androgens | 2 | 2018 | 178 | 0.610 |
Why?
| | Metabolic Syndrome | 3 | 2020 | 355 | 0.610 |
Why?
| | Prevalence | 7 | 2025 | 2855 | 0.600 |
Why?
| | Adolescent | 23 | 2026 | 22485 | 0.600 |
Why?
| | Case-Control Studies | 7 | 2026 | 3619 | 0.590 |
Why?
| | Child, Preschool | 17 | 2026 | 11837 | 0.530 |
Why?
| | Male | 34 | 2026 | 72817 | 0.530 |
Why?
| | Aneuploidy | 5 | 2024 | 90 | 0.520 |
Why?
| | Humans | 47 | 2026 | 145491 | 0.510 |
Why?
| | Electronic Health Records | 3 | 2025 | 1187 | 0.500 |
Why?
| | Female | 29 | 2025 | 78763 | 0.460 |
Why?
| | Infertility, Male | 1 | 2015 | 75 | 0.440 |
Why?
| | Adipose Tissue | 1 | 2019 | 644 | 0.440 |
Why?
| | Hypokalemia | 1 | 2014 | 24 | 0.430 |
Why?
| | Infant, Newborn | 6 | 2025 | 6437 | 0.410 |
Why?
| | Hypertension | 1 | 2022 | 1273 | 0.390 |
Why?
| | Adrenal Hyperplasia, Congenital | 2 | 2025 | 39 | 0.390 |
Why?
| | Double-Blind Method | 4 | 2025 | 2060 | 0.370 |
Why?
| | Infant | 8 | 2025 | 10064 | 0.360 |
Why?
| | Diabetic Ketoacidosis | 1 | 2014 | 210 | 0.350 |
Why?
| | Veterans | 1 | 2024 | 1626 | 0.350 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1076 | 0.340 |
Why?
| | Cohort Studies | 5 | 2025 | 5992 | 0.330 |
Why?
| | Muscle, Skeletal | 1 | 2021 | 1794 | 0.330 |
Why?
| | Obesity | 2 | 2022 | 3076 | 0.310 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5891 | 0.300 |
Why?
| | Follow-Up Studies | 4 | 2025 | 5426 | 0.300 |
Why?
| | Body Mass Index | 3 | 2025 | 2425 | 0.290 |
Why?
| | Body Weight | 2 | 2025 | 970 | 0.280 |
Why?
| | Estradiol | 2 | 2023 | 507 | 0.280 |
Why?
| | Prader-Willi Syndrome | 1 | 2026 | 33 | 0.240 |
Why?
| | Age Determination by Skeleton | 1 | 2026 | 16 | 0.240 |
Why?
| | Autism Spectrum Disorder | 2 | 2025 | 420 | 0.240 |
Why?
| | Chromosomes, Human, Y | 2 | 2021 | 37 | 0.230 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 427 | 0.230 |
Why?
| | Morbidity | 2 | 2024 | 322 | 0.230 |
Why?
| | Epilepsy | 1 | 2010 | 389 | 0.220 |
Why?
| | Karyotype | 2 | 2023 | 19 | 0.220 |
Why?
| | Meta-Analysis as Topic | 1 | 2025 | 171 | 0.210 |
Why?
| | Biological Specimen Banks | 1 | 2025 | 105 | 0.210 |
Why?
| | United Kingdom | 1 | 2025 | 339 | 0.210 |
Why?
| | Blood Glucose | 1 | 2014 | 2330 | 0.210 |
Why?
| | Psychotropic Drugs | 1 | 2025 | 78 | 0.210 |
Why?
| | Reference Values | 1 | 2025 | 797 | 0.210 |
Why?
| | Y Chromosome | 1 | 2023 | 36 | 0.200 |
Why?
| | Adult | 11 | 2025 | 40707 | 0.200 |
Why?
| | Young Adult | 8 | 2024 | 14192 | 0.200 |
Why?
| | Azabicyclo Compounds | 1 | 2022 | 7 | 0.180 |
Why?
| | Oxadiazoles | 1 | 2022 | 37 | 0.180 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2022 | 30 | 0.180 |
Why?
| | Comorbidity | 2 | 2025 | 1659 | 0.170 |
Why?
| | Phosphocreatine | 1 | 2021 | 44 | 0.170 |
Why?
| | Adenosine Diphosphate | 1 | 2021 | 83 | 0.170 |
Why?
| | Mental Health | 2 | 2025 | 795 | 0.170 |
Why?
| | Quality of Life | 2 | 2024 | 3195 | 0.170 |
Why?
| | Genitalia | 1 | 2021 | 34 | 0.170 |
Why?
| | Transgender Persons | 1 | 2024 | 210 | 0.160 |
Why?
| | Gonadotropins | 1 | 2020 | 39 | 0.160 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 324 | 0.150 |
Why?
| | Waist Circumference | 1 | 2020 | 141 | 0.150 |
Why?
| | Genetic Association Studies | 1 | 2021 | 369 | 0.150 |
Why?
| | Developmental Disabilities | 2 | 2016 | 281 | 0.150 |
Why?
| | Hypogonadism | 1 | 2020 | 90 | 0.150 |
Why?
| | Inservice Training | 1 | 2020 | 118 | 0.150 |
Why?
| | Magnetoencephalography | 1 | 2020 | 161 | 0.150 |
Why?
| | Prognosis | 2 | 2019 | 4323 | 0.150 |
Why?
| | Focal Dermal Hypoplasia | 1 | 2019 | 5 | 0.150 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2023 | 302 | 0.150 |
Why?
| | Failure to Thrive | 1 | 2019 | 28 | 0.140 |
Why?
| | Testicular Hormones | 1 | 2018 | 8 | 0.140 |
Why?
| | Adenosine Triphosphate | 1 | 2021 | 503 | 0.140 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2021 | 625 | 0.140 |
Why?
| | Genome-Wide Association Study | 1 | 2025 | 1378 | 0.140 |
Why?
| | Motor Skills Disorders | 1 | 2018 | 25 | 0.140 |
Why?
| | Face | 1 | 2020 | 177 | 0.140 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 196 | 0.140 |
Why?
| | United States | 3 | 2025 | 16115 | 0.140 |
Why?
| | Growth Disorders | 1 | 2019 | 88 | 0.140 |
Why?
| | Mentors | 1 | 2020 | 218 | 0.130 |
Why?
| | Triglycerides | 1 | 2020 | 518 | 0.130 |
Why?
| | Interprofessional Relations | 1 | 2020 | 275 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 165 | 0.130 |
Why?
| | Eosinophilic Esophagitis | 1 | 2021 | 331 | 0.130 |
Why?
| | Overweight | 1 | 2022 | 607 | 0.130 |
Why?
| | Patient Acceptance of Health Care | 1 | 2023 | 884 | 0.120 |
Why?
| | Speech Disorders | 1 | 2016 | 29 | 0.120 |
Why?
| | X Chromosome Inactivation | 1 | 2016 | 25 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2023 | 948 | 0.120 |
Why?
| | Risk | 1 | 2019 | 917 | 0.120 |
Why?
| | Language Development Disorders | 1 | 2016 | 41 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 587 | 0.120 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 909 | 0.120 |
Why?
| | Truth Disclosure | 1 | 2016 | 52 | 0.120 |
Why?
| | Genetic Counseling | 1 | 2016 | 81 | 0.120 |
Why?
| | Algorithms | 1 | 2023 | 1855 | 0.110 |
Why?
| | Research | 1 | 2019 | 432 | 0.110 |
Why?
| | Transcription Factors | 1 | 2023 | 1733 | 0.110 |
Why?
| | Child Behavior Disorders | 1 | 2016 | 118 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 236 | 0.110 |
Why?
| | Mitochondria | 1 | 2021 | 990 | 0.110 |
Why?
| | Potassium | 1 | 2014 | 153 | 0.100 |
Why?
| | Muscle Strength | 1 | 2017 | 332 | 0.100 |
Why?
| | Sex Factors | 1 | 2019 | 2110 | 0.100 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 616 | 0.100 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2945 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2355 | 0.090 |
Why?
| | Insulin Resistance | 1 | 2021 | 1244 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2026 | 11831 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2379 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2950 | 0.090 |
Why?
| | Hypoglycemia | 1 | 2016 | 479 | 0.080 |
Why?
| | Hospitalization | 2 | 2024 | 2458 | 0.080 |
Why?
| | Biomarkers | 2 | 2022 | 4283 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1769 | 0.070 |
Why?
| | Cognition | 1 | 2017 | 1268 | 0.070 |
Why?
| | Brain | 1 | 2020 | 2944 | 0.070 |
Why?
| | Neoplasms | 1 | 2023 | 2897 | 0.060 |
Why?
| | Quality Improvement | 1 | 2016 | 1294 | 0.060 |
Why?
| | Abnormalities, Multiple | 1 | 2008 | 197 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1392 | 0.060 |
Why?
| | Middle Aged | 3 | 2025 | 36176 | 0.060 |
Why?
| | Insulin | 1 | 2016 | 2506 | 0.060 |
Why?
| | Aged | 1 | 2025 | 26125 | 0.050 |
Why?
| | Syndrome | 2 | 2020 | 380 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2582 | 0.050 |
Why?
| | Sexual Development | 1 | 2023 | 17 | 0.050 |
Why?
| | Europe | 1 | 2024 | 421 | 0.050 |
Why?
| | Karyotyping | 1 | 2023 | 105 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 212 | 0.050 |
Why?
| | Menarche | 1 | 2023 | 52 | 0.050 |
Why?
| | 17-alpha-Hydroxyprogesterone | 1 | 2022 | 2 | 0.050 |
Why?
| | Androstenedione | 1 | 2022 | 10 | 0.050 |
Why?
| | Amines | 1 | 2022 | 39 | 0.040 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2022 | 147 | 0.040 |
Why?
| | Thiazoles | 1 | 2022 | 139 | 0.040 |
Why?
| | Prenatal Diagnosis | 1 | 2022 | 196 | 0.040 |
Why?
| | Administration, Oral | 1 | 2022 | 863 | 0.040 |
Why?
| | Counseling | 1 | 2022 | 405 | 0.040 |
Why?
| | Physicians, Women | 1 | 2020 | 88 | 0.040 |
Why?
| | Gene Expression | 1 | 2023 | 1478 | 0.040 |
Why?
| | Genetic Testing | 1 | 2021 | 480 | 0.030 |
Why?
| | Suicidal Ideation | 1 | 2024 | 577 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2023 | 17269 | 0.030 |
Why?
| | Minority Groups | 1 | 2020 | 283 | 0.030 |
Why?
| | Career Choice | 1 | 2020 | 235 | 0.030 |
Why?
| | Peer Group | 1 | 2020 | 258 | 0.030 |
Why?
| | Health Status | 1 | 2023 | 836 | 0.030 |
Why?
| | Universities | 1 | 2020 | 455 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2022 | 2030 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3917 | 0.030 |
Why?
| | Social Media | 1 | 2020 | 167 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1507 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2018 | 311 | 0.030 |
Why?
| | Suicide | 1 | 2024 | 728 | 0.030 |
Why?
| | Incidence | 1 | 2023 | 2915 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 355 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 898 | 0.030 |
Why?
| | Social Support | 1 | 2020 | 651 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 389 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 195 | 0.030 |
Why?
| | Patient Participation | 1 | 2019 | 437 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 383 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2017 | 401 | 0.020 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 557 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2017 | 1139 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1706 | 0.020 |
Why?
| | Physicians | 1 | 2020 | 952 | 0.020 |
Why?
| | Parents | 1 | 2019 | 1404 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7197 | 0.020 |
Why?
| | Anxiety | 1 | 2017 | 1127 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1585 | 0.020 |
Why?
| | Depression | 1 | 2017 | 1573 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 6070 | 0.010 |
Why?
|
|
Davis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|